INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

For patients with R/R MULTIPLE MYELOMA

CHALLENGE EXPECTATIONS

CAR T cell therapy power with a demonstrated safety profile1 and extensive real-world experience*

SEE RESULTS SEE RESULTS
Patient Characteristics

ABECMA is a BCMA-directed therapy studied in a broad patient population1

SEE MORE
Trial Results

View efficacy & safety data from the pivotal KarMMa study

EXPLORE THE DATA
Eligibility & Process

Identify your ABECMA-eligible patients and understand the ABECMA process

GETTING STARTED

Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.

Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.

For patients who experienced NT, including 3 patients with ongoing NT, the median duration of CAR T cell-associated NT was 6 days (range: 1 to 578 days).

BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IRC=Independent Response committee; NT=neurologic toxicity; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory.

For patients with R/R MULTIPLE MYELOMA

CHALLENGE EXPECTATIONS

CAR T cell therapy power with a demonstrated safety profile1 and extensive real-world experience*

SEE RESULTS SEE RESULTS
Patient Characteristics

ABECMA is a BCMA-directed therapy studied in a broad patient population1

SEE MORE
Trial Results

View efficacy & safety data from the pivotal KarMMa study

EXPLORE THE DATA
Eligibility & Process

Identify your ABECMA-eligible patients and understand the ABECMA process

GETTING STARTED

Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.

Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.

For patients who experienced NT, including 3 patients with ongoing NT, the median duration of CAR T cell-associated NT was 6 days (range: 1 to 578 days).

BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IRC=Independent Response committee; NT=neurologic toxicity; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory.